The financials
Agilent Technologies by the numbers
Agilent Technologies (A) reported revenue of $1.83B in Q2 2026 (quarter ended April 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $339M (18% of revenue). For the full year FY2025, revenue was $6.95B (+6.7% year on year) and net income $1.30B. Its largest segment in 2026-Q2 was Life Sciences And Diagnostics Markets at $363M, 48% of the disclosed total, just ahead of Agilent Cross Lab at 38%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.83B | $1.67B | +10% |
| Gross profit | $990M | $866M | +14% |
| Operating income | $399M | $300M | +33% |
| Net income | $339M | $215M | +58% |
| Diluted EPS | $1.20 | $0.75 | +60% |
| Operating | Revenue | Share |
|---|---|---|
| Life Sciences And Diagnostics Markets | $363M | 48% |
| Agilent Cross Lab | $289M | 38% |
| Applied Markets | $112M | 15% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $764.0M (+13%)
Applied Markets grew +35% year on yearAgilent Cross Lab +7.0% year on year
Segment Latestquarter on quarteryear on year
- Life Sciences And Diagnostics Markets$363.0M$363.0MQoQ +18%year on year +12%+18%+12%
- Agilent Cross Lab$289.0M$289.0MQoQ +5.9%year on year +7.0%+5.9%+7.0%
- Applied Markets$112.0M$112.0MQoQ +14%year on year +35%+14%+35%
Diagnostics & Research
Ranks #16 of 29 by Smart Score